Condensed Statements of Operations - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
Jun. 30, 2022 |
Jun. 30, 2021 |
Jun. 30, 2022 |
Jun. 30, 2021 |
Dec. 31, 2021 |
Dec. 31, 2020 |
|
| Income Statement [Abstract] | ||||||
| REVENUES, net | ||||||
| COST OF REVENUES | ||||||
| GROSS MARGIN | ||||||
| OPERATING EXPENSES: | ||||||
| General and administrative expenses | 407,697 | 2,490,597 | 1,155,344 | 3,099,185 | 4,211,355 | 4,598,302 |
| Research and development | 553,692 | 95,141 | 1,092,453 | 95,141 | 779,275 | |
| Impairment of long-lived assets | 15,000 | 16,958 | 32,136 | |||
| Depreciation and amortization | 1,990 | 2,005 | 3,979 | 2,765 | 6,744 | 5,301 |
| Salaries | ||||||
| Professional fees | ||||||
| Total operating expenses | 963,379 | 2,587,743 | 2,251,776 | 3,212,091 | 5,014,332 | 4,635,739 |
| LOSS FROM OPERATIONS | (963,379) | (2,587,743) | (2,251,776) | (3,212,091) | (5,014,332) | (4,635,739) |
| OTHER EXPENSES | ||||||
| Interest expense | 324,106 | 8,011 | 431,928 | 176,672 | 176,672 | 34,516 |
| Loss on debt extinguishment | 149,350 | |||||
| Total other expense | 324,106 | 8,011 | 431,928 | 176,672 | 326,022 | 34,516 |
| Net loss | (1,287,485) | (2,595,754) | (2,683,704) | (3,388,763) | (5,340,354) | (4,670,255) |
| Series C deemed dividend | (566,946) | (22,179) | (12,182,310) | (13,477,055) | (4,440) | |
| Net loss to common shareholders | $ (1,287,485) | $ (3,162,700) | $ (2,705,883) | $ (15,571,073) | $ (18,817,409) | $ (4,674,695) |
| Loss per weighted average common share, basic and diluted | $ (0.00) | $ (0.01) | $ (0.00) | $ (0.03) | $ (0.04) | $ (0.01) |
| Number of weighted average common shares outstanding, basic and diluted | 571,651,636 | 529,253,750 | 571,474,288 | 452,174,976 | 500,981,957 | 326,678,469 |
| X | ||||||||||
- Definition Earnings per shares combination. No definition available.
|
| X | ||||||||||
- Definition Salaries. No definition available.
|
| X | ||||||||||
- Definition Weighted average number of shares outstanding combination. No definition available.
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders. No definition available.
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|